ARS Pharmaceuticals

ARS Pharmaceuticals, based in San Diego, CA, specializes in developing needle-free treatments for severe allergic reactions. The company is currently focused on creating a needle-free nasal spray designed to deliver epinephrine, which aims to reduce hesitation and allow patients to confidently administer the medication when needed. Recognizing the pitfalls of current treatments, such as fear of needles, needle-related injuries, device bulkiness, and complexity of administration, ARS Pharmaceuticals is committed to addressing these issues with their innovative solutions.

Approximately 25 to 40 million people in the United States have experienced severe Type 1 allergic reactions that may lead to anaphylaxis, yet only about 3.3 million people filled a prescription for an epinephrine intra-muscular injectable device in 2021. ARS Pharmaceuticals is developing neffy™ (ARS-1), a low-dose intranasal epinephrine nasal spray intended for use as a rescue medication at the first signs of an allergic response. This product aims to improve patient and caregiver preparedness and response, providing a new option to rapidly resolve symptoms and prevent progression to severe anaphylaxis. The device features needle-free administration, a proven design used by current emergency therapies, a pocket-sized form factor, and eliminates the risk of needle-related injuries. However, it is important to note that this product is still under investigation and is not yet FDA approved.

The company offers a range of employee benefits, including healthcare, financial, wellness, and voluntary coverage options, with most positions eligible for remote or flexible hybrid schedules. ARS Pharmaceuticals is dedicated to providing reasonable accommodations to qualified individuals with disabilities. The company’s mission is to develop treatments that help eliminate the anxiety and hesitation associated with using injectable devices, empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis.